Trump's drug price plan expected to push drugmakers to charge same as other countries
Read Original Source
President Donald Trump will announce a plan to lower U.S. prescription drug costs by tying the amount the government pays for some medications to prices paid abroad, according to two administration officials familiar with the matter — a strategy he pursued unsuccessfully during his first term. Limited time: Save 25% on NBC News subscription Get exclusive reporting, live Q&As and ad-free reading.
AI Summary
Main Idea: Trump is set to announce a plan that would tie some U.S. Medicare drug payments to the lowest prices paid in other wealthy countries, aiming to cut prescription costs.
Key Points:
- The executive order would use a “most favored nation” pricing model for certain Medicare-covered drugs.
- The idea is to make drugmakers charge the U.S. no more than they charge in countries like Canada, Germany, and the U.K.
- Trump tried a similar plan in 2020, but a court stopped it after a lawsuit from the drug industry.
- The drug industry group PhRMA is expected to fight the plan, while Medicare drug price negotiations under Biden’s law remain another possible route to lower costs.
Impact on the People
Negative Impact
Drugmakers may fight the plan in court, so lower prices for patients and taxpayers could be delayed or limited.
Positive Impact
If CMS adopts the rule, Medicare and some seniors could pay less for costly medicines, easing household drug bills.
How did each entity affect people?
Rate how each entity in this article affected the American people.
No entity suggestions or linked entities saved yet.
Candidate Entities9 candidates · 5 weighted vote min · 70% decision
- President Donald TrumppersonPrimaryAI selected
Central actor expected to announce the drug pricing plan and sign the executive order.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Centers for Medicare and Medicaid Servicesgovernment agency or bodyMajorAI selected
Federal agency that would implement the pricing and is also referenced on Medicare drug negotiations.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Pharmaceutical Research and Manufacturers of Americaunion / trade associationMajorAI selected
Named drug industry trade group directly opposing the policy and tied to the prior lawsuit.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Arthur CaplanpersonContextCandidate
Named expert quoted in support of the approach; meaningful commentary but not central.
Include 0 (0%)Ignore 0 (0%)5 to threshold - President Joe BidenpersonContextCandidate
Former president whose administration’s drug pricing law and actions are part of the policy context.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Stacie DusetzinapersonContextCandidate
Named expert quoted assessing likely legal and industry pushback.
Include 0 (0%)Ignore 0 (0%)5 to threshold - Tricia NeumanpersonContextCandidate
Named expert quoted on public support and opposition to the policy.
Include 0 (0%)Ignore 0 (0%)5 to threshold
Comments 0
Comments here are the same thread shown when this article appears in The Pulse.
No comments on this article yet.
Sign in to comment